1. 1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. (September 2015) Authors: Lüftner, D.; Grischke, E.M.; Fasching, P.; Decker, T.; Schneeweiss, A.; Uleer, C.; Foerster, F.; Wimberger, P.; Kluth-Pepper, B.; Schubert, J.; Bloch, W.; Tesch, H.; Schuetz, F.; Jackisch, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S288 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. (June 2019) Authors: Mavratzas, A.; Baek, S.; Gerber, B.; Schmidt, M.; Moebus, V.; Foerster, F.; Grischke, E.M.; Fasching, P.; Strumberg, D.; Solomayer, E.; Klare, P.; Windemuth-Kieselbach, C.; Hartmann, S.; Schneeweiss, A.; Marmé, F. Journal: Breast Issue: Volume 45(2019) Page Start: 22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). (3rd August 2019) Authors: Moehler, M.; Heo, J.; Lee, H.C.; Tak, W.Y.; Chao, Y.; Paik, S.W.; Yim, H.J.; Byun, K.S.; Baron, A.; Ungerechts, G.; Jonker, D.; Ruo, L.; Cho, M.; Kaubisch, A.; Wege, H.; Merle, P.; Ebert, O.; Habersetzer, F.; Blanc, J.F.; Rosmorduc, Olivier Journal: Oncoimmunology Issue: Volume 8:Number 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗